Hardwick,, United Kingdom Clinical Trials

A listing of Hardwick,, United Kingdom clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 216 clinical trials
PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V

COVID-19 (novel coronavirus-induced disease) was declared a global pandemic by the WHO on 11th March 2020. Currently there are no drugs proven to prevent COVID-19 or to reduce the severity of illness if given as prophylaxis. Although vaccines are now available, there remains a need for other prophylactic agents until …

Cambridge University Hospitals NHS Foundation Trust
 (4.1 away) Contact site
  • 0 views
  • 11 May, 2021
  • 1 location
A Study to Test Safety and Efficacy of BI456906 in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)

This study is open for men and women with a liver disease called nonalcoholic steatohepatitis (NASH) and liver fibrosis. The purpose of the study is to find out whether a medicine called BI 456906 helps patients with NASH and liver fibrosis. The study tests 3 different doses of BI 456906 …

Addenbrooke's Hospital
 (4.5 away) Contact site
  • 0 views
  • 15 Sep, 2021
  • +59 other locations
A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis

Study CC-93538-EE-001 is a Phase 3, multicenter, multinational, randomized, double-blind, placebo-controlled induction and maintenance study to evaluate the efficacy and safety of CC- 93538 in adult and adolescent participants with eosinophilic esophagitis (EoE). The study will incorporate a 24-week Induction Phase followed by a 24-week Maintenance Phase. Participants will be …

Addenbrooke's Hospital
 (4.5 away) Contact site
  • 42 views
  • 28 Aug, 2021
  • +228 other locations
HElping Alleviate the Longer-term Consequences of COVID-19 (HEAL-COVID)

HEAL-COVID is jointly Sponsored by Cambridge University Hospitals NHS Foundation Trust and The University of Cambridge. The acute effects of COVID-19 are now well described. Evidence is emerging of serious longer-term complications occurring in the convalescent phase of the illness in a significant proportion of patients particularly cardiovascular and pulmonary …

Addenbrookes Hospital
 (4.8 away) Contact site
  • 0 views
  • 02 Aug, 2021
  • 1 location
Adalimumab vs. Conventional Immunosuppression for Uveitis Trial

Non-infectious intermediate, posterior, and panuveitides are chronic, potentially-blinding diseases. Vision-threatening cases require long-term therapy with oral corticosteroids and immunosuppression. Based upon preliminary data, adalimumab, a fully-human, anti-TNFmonoclonal antibody, now US FDA-approved for uveitis treatment, may be a superior corticosteroid-sparing agent than conventional immunosuppressive drugs. The ADVISE Trial is multicenter randomized, …

corticosteroids
cyclosporine
immunosuppressive agents
monoclonal antibodies
methotrexate
Cambridge University NHS Trust
 (6.1 away) Contact site
  • 111 views
  • 02 Aug, 2021
  • +32 other locations
Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury

The purpose of this study is to determine whether a single treatment with administration of 400 Units NT 201 (botulinum toxin) is superior to placebo (no medicine) for the treatment of lower limb spasticity caused by stroke or traumatic brain injury (Main Period). Participants will be assigned to the treatment …

Cambridge University Hospitals NHS Foundation Trust; Merz Investigational Site 0440023
 (6.1 away) Contact site
  • 28 views
  • 19 Sep, 2021
  • +62 other locations
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low Hormone Receptor Positive Metastatic Breast Cancer

This study will evaluate the efficacy, safety and tolerability of trastuzumab deruxtecan compared with investigator's choice chemotherapy in human epidermal growth factor receptor (HER)2-low, hormone receptor (HR) positive breast cancer patients whose disease has progressed on endocrine therapy in the metastatic setting.

Research Site
 (6.1 away) Contact site
  • 37 views
  • 19 Sep, 2021
  • +277 other locations
Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasis

This is a multicentre, randomised, double-blind, parallel-group, placebo-controlled, 52 week Phase III study to test the hypothesis that benralizumab will reduce exacerbation rates compared with placebo on top of standard-of-care therapy in adult patients with non-cystic fibrosis bronchiectasis with eosinophilic inflammation (NCFB+EI). All patients who complete the 52-week double-blind treatment …

Research Site
 (6.1 away) Contact site
  • 1 views
  • 19 Sep, 2021
  • +100 other locations
Irinotecan With or Without Panitumumab or Cyclosporine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Fluorouracil

RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cyclosporine may help irinotecan work better by making tumor cells more sensitive to the drug. Monoclonal antibodies, such as panitumumab, …

monoclonal antibodies
irinotecan
tumor growth
tumor cells
metastatic colorectal cancer
Addenbrooke's Hospital
 (4.5 away) Contact site
  • 130 views
  • 07 Nov, 2020
  • +11 other locations
Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD)

The main purpose of this study is to see if a drug called aldesleukin, can preserve insulin production in children and young adults recently diagnosed with type 1 diabetes. One group will receive aldesleukin and the other a placebo.

Addenbrooke's Hospital
 (4.8 away) Contact site
  • 3 views
  • 01 Feb, 2021
  • +5 other locations